• Explore /
  • Poster
  • / KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.

KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.

Abstract Poster

Authors

Yelena Janjigian

Yelena Yuriy Janjigian

Memorial Sloan Kettering Cancer Center, New York, NY

Yelena Yuriy Janjigian , Yung-Jue Bang , Charles S. Fuchs , Shukui Qin , Taroh Satoh , Kohei Shitara , Josep Tabernero , Eric Van Cutsem , Z. Alexander Cao , Xinqun Chen , S. Peter Kang , Chie-Schin Shih , Hyun Cheol Chung

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03615326

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS4146)

DOI

10.1200/JCO.2019.37.15_suppl.TPS4146

Abstract #

TPS4146

Poster Bd #

248b

Abstract Disclosures

Similar Posters

First Author: Hyun Cheol Chung

First Author: Zev A. Wainberg

First Author: Yelena Y. Janjigian

First Author: Haeseong Park